{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:32:47Z","timestamp":1760243567704,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"COST","award":["CA17104"],"award-info":[{"award-number":["CA17104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer drug resistance, either intrinsic or acquired, often causes treatment failure and increased mortality [...]<\/jats:p>","DOI":"10.3390\/cancers14225491","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T02:34:52Z","timestamp":1667961292000},"page":"5491","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue: \u201cNew Diagnostic and Therapeutic Tools against Multidrug-Resistant Tumors (STRATAGEM Special Issue, EU-COST CA17104)\u201d"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-4643","authenticated-orcid":false,"given":"M. Helena","family":"Vasconcelos","sequence":"first","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"Department of Biological Sciences, FFUP\u2014Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-7839","authenticated-orcid":false,"given":"Catherine","family":"Passirani","sequence":"additional","affiliation":[{"name":"Micro et Nanom\u00e9decines Translationnelles, MINT, UNIV Angers, UMR INSERM 1066, UMR CNRS 6021, SFR ICAT, 49000 Angers, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-4836","authenticated-orcid":false,"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Torino, Via Santena 5\/bis, 10126 Torino, Italy"},{"name":"Interdepartmental Research Center for Molecular Biotechnology \u201cG. Tarone\u201d, University of Torino, Via Nizza 52, 10126 Torino, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.drup.2019.100646","article-title":"The emergence of drug resistance to targeted cancer therapies: Clinical evidence","volume":"47","author":"Scorilas","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100643","DOI":"10.1016\/j.drup.2019.100643","article-title":"What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg","volume":"46","author":"Trougakos","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100797","DOI":"10.1016\/j.drup.2021.100797","article-title":"Impact of cancer metabolism on therapy resistance-Clinical implications","volume":"59","author":"Richiardone","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100715","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100670","DOI":"10.1016\/j.drup.2019.100670","article-title":"Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets","volume":"49","author":"Kopecka","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.drup.2019.100647","article-title":"Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance","volume":"47","author":"Vasconcelos","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100662","DOI":"10.1016\/j.drup.2019.100662","article-title":"Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions","volume":"48","author":"Tolios","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100682","DOI":"10.1016\/j.drup.2020.100682","article-title":"Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors","volume":"50","author":"Dallavalle","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.drup.2020.100704","article-title":"Nanomedicine to target multidrug resistant tumors","volume":"52","author":"Lepeltier","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100789","DOI":"10.1016\/j.drup.2021.100789","article-title":"Molecular Modeling Strategies of Cancer Multidrug Resistance","volume":"59","year":"2021","journal-title":"Drug Resist. Updates"},{"doi-asserted-by":"crossref","unstructured":"Mohr, T., Katz, S., Paulitschke, V., Aizarani, N., and Tolios, A. (2021). Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. Cancers, 13.","key":"ref_13","DOI":"10.3390\/cancers13081768"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100658","DOI":"10.1016\/j.drup.2019.100658","article-title":"Advanced technological tools to study multidrug resistance in cancer","volume":"48","author":"Andrei","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10637-019-00803-6","article-title":"CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells","volume":"38","author":"Karpaviciene","year":"2020","journal-title":"Investig. New Drugs"},{"doi-asserted-by":"crossref","unstructured":"Dobiasov\u00e1, S., \u0158eho\u0159ov\u00e1, K., Ku\u010derov\u00e1, D., Biedermann, D., K\u00e1\u0148ov\u00e1, K., Petr\u00e1skov\u00e1, L., Kouck\u00e1, K., V\u00e1clav\u00edkov\u00e1, R., Valentov\u00e1, K., and Ruml, T. (2020). Multidrug Resistance Modulation Activity of Silybin Derivatives and Their Anti-inflammatory Potential. Antioxidants, 9.","key":"ref_16","DOI":"10.3390\/antiox9050455"},{"key":"ref_17","first-page":"676","article-title":"Molecular mechanisms of docetaxel resistance in prostate cancer","volume":"3","author":"Sekino","year":"2020","journal-title":"Cancer Drug Resist."},{"doi-asserted-by":"crossref","unstructured":"Lima, T.S., Iglesias-Gato, D., Souza, L.D.O., Stenvang, J., Lima, D.S., R\u00f8der, M.A., Brasso, K., and Moreira, J.M.A. (2021). Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. Cancers, 13.","key":"ref_18","DOI":"10.3390\/cancers13061290"},{"doi-asserted-by":"crossref","unstructured":"Neophytou, C.M., Trougakos, I.P., Erin, N., and Papageorgis, P. (2021). Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers, 13.","key":"ref_19","DOI":"10.3390\/cancers13174363"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11899-019-00543-7","article-title":"Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors","volume":"14","author":"Yaghmaie","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"doi-asserted-by":"crossref","unstructured":"Alves, R., Gon\u00e7alves, A.C., Rutella, S., Almeida, A.M., De Las Rivas, J., Trougakos, I.P., and Sarmento Ribeiro, A.B. (2021). Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance. Cancers, 13.","key":"ref_21","DOI":"10.3390\/cancers13194820"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"doi-asserted-by":"crossref","unstructured":"Podolski-Reni\u0107, A., Dini\u0107, J., Stankovi\u0107, T., Tsakovska, I., Pajeva, I., Tuccinardi, T., Botta, L., Schenone, S., and Pe\u0161i\u0107, M. (2021). New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo [3,4-d]pyrimidine Tyrosine Kinase Inhibitors. Cancers, 13.","key":"ref_23","DOI":"10.3390\/cancers13215308"},{"doi-asserted-by":"crossref","unstructured":"Szemer\u00e9di, N., Dobiasov\u00e1, S., Salard\u00f3n-Jim\u00e9nez, N., Kincses, A., Nov\u00e9, M., Habibullah, G., Sevilla-Hern\u00e1ndez, C., Benito-Lama, M., Alonso-Mart\u00ednez, F.J., and Viktorov\u00e1, J. (2021). Cyano- and Ketone-Containing Selenoesters as Multi-Target Compounds against Resistant Cancers. Cancers, 13.","key":"ref_24","DOI":"10.3390\/cancers13184563"},{"doi-asserted-by":"crossref","unstructured":"Kladnik, J., Coverdale, J.P.C., Kljun, J., Burmeister, H., Lippman, P., Ellis, F.G., Jones, A.M., Ott, I., Romero-Canel\u00f3n, I., and Turel, I. (2021). Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells. Cancers, 13.","key":"ref_25","DOI":"10.3390\/cancers13102493"},{"doi-asserted-by":"crossref","unstructured":"Idlas, P., Lepeltier, E., Jaouen, G., and Passirani, C. (2021). Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors. Cancers, 13.","key":"ref_26","DOI":"10.3390\/cancers13102291"},{"doi-asserted-by":"crossref","unstructured":"Pautu, V., Lepeltier, E., Mellinger, A., Riou, J., Debuigne, A., J\u00e9r\u00f4me, C., Clere, N., and Passirani, C. (2021). pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization. Cancers, 13.","key":"ref_27","DOI":"10.3390\/cancers13092028"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sinica. B"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat. Rev. Genet."},{"doi-asserted-by":"crossref","unstructured":"Barbosa, M.A.G., Xavier, C.P.R., Pereira, R.F., Petrikait\u0117, V., and Vasconcelos, M.H. (2021). 3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs. Cancers, 14.","key":"ref_30","DOI":"10.3390\/cancers14010190"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5491\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:46Z","timestamp":1760145166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/22\/5491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":30,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14225491"],"URL":"https:\/\/doi.org\/10.3390\/cancers14225491","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,11,8]]}}}